ABCELLERA BIOLOGICS INC (ABCL)
CA00288U1066 - Common Stock
ChartMill assigns a Buy % Consensus number of 84% to ABCL. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 15.68. This target is 332.02% above the current price.
ABCL was analyzed by 15 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about ABCL.
In the previous month the buy percentage consensus was at a similar level.
ABCL was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-02-22 | Benchmark | Upgrade | Hold -> Buy |
| 2024-02-21 | Stifel | Maintains | Buy -> Buy |
| 2023-12-05 | Keybanc | Initiate | Overweight |
| 2023-08-31 | Benchmark | Maintains | Buy -> Buy |
| 2023-08-04 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023-05-05 | Credit Suisse | Maintains | Outperform |
| 2023-02-28 | Cowen & Co. | Initiate | Outperform |
| 2023-02-22 | BMO Capital | Maintains | Outperform |
| 2023-02-22 | Credit Suisse | Reiterate | Outperform |
| 2023-01-06 | SVB Leerink | Maintains | Outperform |
| 2022-12-15 | Goldman Sachs | Initiate | Buy |
| 2022-11-16 | Truist Securities | Initiate | Buy |
| 2022-11-09 | SVB Leerink | Maintains | Outperform |
| 2022-08-10 | Credit Suisse | Maintains | Outperform |
| 2022-07-26 | Piper Sandler | Maintains | Overweight |
| 2022-05-11 | SVB Leerink | Maintains | Outperform |
| 2022-05-11 | Piper Sandler | Maintains | Overweight |
| 2022-02-25 | SVB Leerink | Maintains | Outperform |
| 2022-02-25 | Credit Suisse | Maintains | Outperform |
| 2021-12-21 | Benchmark | Initiate | Buy |
| 2021-11-19 | Piper Sandler | Initiate | Overweight |
| 2021-08-13 | Credit Suisse | Maintains | Outperform |
| 2021-05-14 | Credit Suisse | Maintains | Outperform |
| 2021-03-30 | Stifel | Maintains | Buy |
| 2021-02-08 | SVB Leerink | Maintains | Outperform |